GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
about
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSGroup II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortexA novel mass spectrometry-based assay for GSK-3beta activity.Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and ImagingWNT and beta-catenin signalling: diseases and therapiesSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergenceUpregulation of GSK3β Contributes to Brain Disorders in Elderly REGγ-knockout MiceCognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Neurodevelopment in schizophrenia: the role of the wnt pathways.Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase.No association between polymorphisms of WNT2 and schizophrenia in a Korean populationBlocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model.Different susceptibility to neurodegeneration of dorsal and ventral hippocampal dentate gyrus: a study with transgenic mice overexpressing GSK3β.Wnt2 expression and signaling is increased by different classes of antidepressant treatments.Symmetric abnormalities in sulcal patterning in schizophrenia.Deregulation of the phosphatidylinositol-3 kinase signaling cascade is associated with neurodegeneration in Npc1-/- mouse brain.Synaptic Wnt signaling-a contributor to major psychiatric disorders?Common variants in the MKL1 gene confer risk of schizophrenia.Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brainCommon genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's diseaseVital elements of the Wnt-Frizzled signaling pathway in the nervous system.Winding through the WNT pathway during cellular development and demiseThe wnt pathway in mood disordersDaydreamer, a Ras effector and GSK-3 substrate, is important for directional sensing and cell motilityWnt signaling and human diseases: what are the therapeutic implications?Targeting of neurotrophic factors, their receptors, and signaling pathways in the developmental neurotoxicity of organophosphates in vivo and in vitro.The Frizzled 3 gene is associated with methamphetamine psychosis in the Japanese population.The role of GSK-3 in synaptic plasticity.Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.Activity-dependent regulation of dendritic growth and maintenance by glycogen synthase kinase 3βTargets and consequences of protein SUMOylation in neurons.GSK-3β activity and hyperdopamine-dependent behaviorsA gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia.Microvascular anomaly conditions in psychiatric disease. Schizophrenia - angiogenesis connection.α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.Aberrant Wnt signaling: a special focus in CNS diseases.Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases.Hyperdopaminergic modulation of inhibitory transmission is dependent on GSK-3β signaling-mediated trafficking of GABAA receptors.GSK3β Hyperactivity during an Early Critical Period Impairs Prefrontal Synaptic Plasticity and Induces Lasting Deficits in Spine Morphology and Working Memory.
P2860
Q21129334-6DBD6EC8-5C05-4B1B-BCC2-9A69D54B4302Q24612550-0CE8A68D-6EF7-467C-BD18-BA3AADD023CDQ25257396-2F02AA64-EAE7-42DE-8D41-A7EFB27AC4C0Q26768475-B590B48B-FDCE-4CDF-960D-F53AE48AFFB3Q29616159-0E599F71-D63A-47D3-960B-9C5AD44D19AFQ29618819-7981ED06-CB62-4F20-A32F-16DEE90960F3Q30359981-981E4FDA-E0B4-42EE-A246-D1F497FBA486Q30396291-235BADB9-C644-438B-B63C-19B9927C586AQ30442237-530A8267-7C6F-4EA2-BFAC-937B7AEE20EEQ30465622-9661A0EB-8070-42A2-ADA8-00829B44DBF3Q33584404-883173AB-05FA-418B-8063-3469415C6643Q33810933-9C814479-ED93-41B3-A532-8640DDBE2050Q34071884-809312D9-BC46-4926-BF97-6F8E73DB1D36Q34088354-472071CB-C29A-41C1-B5F0-319F28454998Q34446785-29E78D46-92B3-4DB4-B2E2-1734AAD8AE95Q35085261-17414CCA-4E77-4308-93ED-5C25246C98DFQ35234350-49FEF7C2-2D16-4E84-A87C-0BA63F1D643CQ35369852-DBC5B6F4-8952-4043-8C9D-C9A6CAB9B9B7Q35748119-D0EE6CAE-E456-44D6-8EB8-869FB098DA46Q35748124-A2CED165-8B27-4510-BC91-F1584A5965EDQ35839636-A3F51656-702B-4B5B-8951-C0C64EE0C4CCQ36266255-43DCBFB1-2BBA-447D-A30E-5556AE6CBD3EQ36305544-5E6A060B-BDDD-4E37-A340-029CCCB033CCQ36310513-58E7D200-A101-4419-B332-751C9248F592Q36523579-7FF3D3ED-E068-40B8-AF5A-99C04F9451D7Q36702732-45C6F4B0-1FE6-42E1-BCF7-BC27DEBBFCD9Q36725915-7CBD2D48-D2C6-4540-969C-EB8C2F433A1DQ36889827-74B7A2B8-3C40-44D1-95D2-C6E99828018BQ37098587-22AB614A-AB36-46B4-9A8B-18C983E96476Q37139258-3D45A91A-3FD1-427F-A4F0-01B15D59C276Q37292338-D3C99ABA-8293-48FF-AE47-FC170F604B5DQ37728628-56F44282-EB87-41B5-9B18-542025DED9DEQ37781424-B720C89E-A8E4-41D1-B603-DDA3123502E4Q38496254-A700C47F-79FC-4C2A-AFA1-229121E7661AQ39232878-527A5107-4F79-46F0-B489-44E8D00A5A8FQ39279185-72F22E98-DD43-4EBD-99A9-2BD6D4F213FEQ39387696-9631A553-D454-4F24-88D7-90EF69C2A131Q40365362-A8E58A6D-402E-4128-B588-8BB17C00D53FQ42325582-99C22794-D05A-4507-A47A-0BD77064B4C1Q44693159-97B4800A-AAAC-45EF-B5C4-6BB9A56FA93B
P2860
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@ast
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@en
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@nl
type
label
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@ast
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@en
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@nl
prefLabel
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@ast
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@en
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@nl
P2093
P1476
GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
@en
P2093
Galila Agam
Nitsan Kozlovsky
R H Belmaker
P356
10.1016/S0924-977X(01)00131-6
P407
P577
2002-02-01T00:00:00Z